Aviron nasal spray flu vaccine PLA filing in children and adults planned for mid-1998.
AVIRON NASAL SPRAY FLU VACCINE PLA FILING PLANNED FOR MID-1998 based on data from a Phase III trial in children and an upcoming study in healthy adults. Mountain View, Calif.-based Aviron and the National Institute of Allergy and Infectious Diseases, which co-funded the pediatric trial, announced initial results of the study with the live, attenuated cold-adapted influenza vaccine on July 14.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth